Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate
Cocrystal Pharma Inc (NASDAQ:COCP) selected CDI-988 for clinical development as an oral treatment for COVID-19. CDI-988 targeted a highly conserved…
Cocrystal Pharma Selects CDI-988 For Clinical Development As An Oral Treatment For COVID-19
BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development as an
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.
